Charles A. Deignan, Chief Financial Officer at Clearside Biomedical, Inc. (CLSD), bought 500 shares at $11.79 ($6K) on 2018-03-23, disclosed to the SEC on 2018-03-26.
Open-market purchase of $6k CLSD by Chief Financial Officer. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| CLSD | SELL | 2022-01-20 | $18K | — | Filing → |
| CLSD | SELL | 2021-09-23 | $18K | — | Filing → |
| CLSD | SELL | 2021-06-23 | $13K | — | Filing → |